13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,342 薬物数 : 2,380 - (DrugBank : 407) / 標的遺伝子数 : 266 - 標的パスウェイ数 : 240

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03109288
(ClinicalTrials.gov)
August 11, 201711/4/2017Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Multiple SclerosisDrug: Pioglitazone;Drug: clemastine fumarate;Drug: Dantrolene;Drug: PirfenidoneNational Institute of Allergy and Infectious Diseases (NIAID)NULLRecruiting18 YearsN/AAll250Phase 1/Phase 2United States
2NCT00242177
(ClinicalTrials.gov)
October 200318/10/2005Pilot Test of ACTOS in Multiple Sclerosis: Safety and TolerabilityPilot Test of ACTOS in Multiple Sclerosis: Safety and TolerabilityMultiple Sclerosis, Relapsing-RemittingDrug: ACTOS (Pioglitazone)University of Illinois at ChicagoTakeda Pharmaceuticals North America, Inc.Completed18 Years65 YearsAll30Phase 1United States